Categorynews

Repair Biotechnologies Raises $2.15M Seed Round to Develop Drugs for Age-Related Diseases

May 7, 2019 Off By BusinessWire

SYRACUSE, N.Y.–(BUSINESS WIRE)–Repair Biotechnologies, Inc. announced today $2.15 million in seed
venture funding, to accelerate the preclinical development of its
pipeline of drugs targeting thymus regeneration, cancer, and
atherosclerosis.

The $2.15 million in funding was led by Jim Mellon, the billionaire
investor and Chairman of Juvenescence Ltd. Also participating in the
round are Emerging Longevity Ventures, Thynk Capital, and SENS Research
Foundation.

“We are committed to developing treatments for the root causes of aging
and its associated diseases through the damage repair approach,” said
Reason, co-founder and CEO. “With this funding round, we will be able to
further develop our therapies and validate them in animal models,
bringing them closer to the clinic and patients.”

The thymus gland is vital to the adaptive immune system, but with age,
the thymus shrinks, leading to a decreased immune cell production and a
compromised immune system. Repair Biotechnologies is developing a
therapy with the aim of reverting this atrophy of the thymus, which the
company believes can be an effective treatment against some forms of
cancer.

Repair Biotechnologies’ second major project relates to atherosclerosis,
which is caused by the accumulation of intracellular waste in arteries.
While present therapies focus on reducing cholesterol, Repair
Biotechnologies has licensed a technology to make the macrophage cells
responsible for repairing arteries resilient to excess cholesterol, and
thus able to repair atherosclerotic damage.

“SENS Research Foundation was founded to push forward proof-of-concept
work demonstrating the validity of the SENS paradigm to the point at
which people can actually do something with it. Now we’re seeing some of
these technologies getting the recognition from investors that they
deserve, which in turn is driving critical growth in the private-sector
side of the field,” said Aubrey de Grey, co-founder and Chief Science
Officer of SENS Research Foundation. “I’m thrilled to see Repair
Biotechnologies taking things in this area to the next level.”

About Repair Biotechnologies:

Repair Biotechnologies, Inc. is a biotechnology company with the mission
to develop and bring to the clinic therapies that significantly improve
human healthspan through targeting the causes of age-related diseases
and aging itself. Founded in 2018, Repair Biotechnologies is developing
therapies with the goals of regenerating the thymus, treating cancer,
and reversing atherosclerosis.

www.repairbiotechnologies.com